Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Whether you're working with research peptides, GLP-1 medications, or custom peptide blends, our free peptide calculator helps you determine the exact measurements needed for safe and effective peptide administration
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
It is also useful in improving blood flow by boosting the production of nitric oxide in the body
Nov 1997;12(6):946-951
Our GLP-1 receptor agonist was purchased from a major pharmaceutical wholesaler
